Biotech Scan
Scan
Biotech Scan
raw scan snapshot — prices as of scan date, not live 56 rows · screens, not recommendations superseded by2026-04-26-biotech-scanported fromresearch/classic/scans/_archive/2026-03-20-biotech-scan.mdscan slugbiotech-scansource typescan-archive
Sector-wide selloff deepening — ABBV joins MDT/A in extreme oversold territory (RSI 25-28), LLY at RSI 30 approaching its first real capitulation, while PTGX and MRNA remain the only names showing genuine strength.
Quick Snapshot
| Signal | Reading |
|---|---|
| Overall | 🔴 BEARISH / BROAD SELLOFF — Nearly all names trending down, life science tools and large-cap pharma under pressure |
| Leaders | PTGX ($98.85, RSI 62), MRNA ($51.39, RSI 51), EXAS ($104.96, RSI 76↑) — working in a broken sector |
| Laggards | MDT ($86.32, RSI 25↓), ABBV ($204.75, RSI 28↓), BMRN ($54.25, RSI 29↓) — capitulation territory |
Price Table (2026-03-20)
| Stock | Price | RSI | vs SMA20 | 7D% | 30D% | Trend | Signal |
|---|---|---|---|---|---|---|---|
| ECL | $254.95 | 18 ↓ | -10.6% | -6.5% | -16.0% | down | 🟢 Extreme Oversold |
| MDT | $86.32 | 25 ↓ | -6.3% | -0.8% | -10.9% | down | 🟢 Extreme Oversold |
| ABBV | $204.75 | 28 ↓ | -8.9% | -8.1% | -8.9% | down | 🟢 Extreme Oversold |
| BMRN | $54.25 | 29 ↓ | -8.7% | -7.3% | -15.3% | down | 🟢 Extreme Oversold |
| A | $110.47 | 28 ↓ | -5.4% | +0.1% | -10.1% | strong-down | 🟢 Extreme Oversold |
| LLY | $903.48 | 30 ↓ | -8.9% | -7.8% | -10.5% | weak-down | 🟢 Oversold |
| DHR | $188.74 | 33 ↓ | -5.2% | +2.0% | -9.9% | down | 🟡 Approaching Oversold |
| TMO | $472.83 | 34 ↓ | -4.7% | -0.1% | -7.4% | down | 🟡 Approaching Oversold |
| INCY | $90.61 | 33 ↓ | -6.0% | +0.3% | -10.6% | weak-down | 🟡 Approaching Oversold |
| IONS | $70.83 | 31 ↓ | -7.4% | -1.9% | -14.8% | weak-down | 🟡 Approaching Oversold |
| RARE | $20.03 | 34 ↓ | -8.8% | -8.0% | -11.8% | strong-down | ❌ Falling Knife |
| NVO | $36.52 | 31 ↓ | -4.3% | -3.6% | -23.0% | strong-down | ❌ Falling Knife |
| BNTX | $87.69 | 36 ↓ | -11.2% | -1.7% | -20.4% | down | 🔴 Breakdown |
| CRSP | $46.40 | 37 ↓ | -14.0% | -4.5% | -13.2% | strong-down | 🔴 Breakdown |
| RXRX | $3.27 | 38 ↓ | -6.4% | -2.9% | -4.4% | strong-down | ❌ Avoid |
| ALNY | $314.53 | 40 ↓ | -2.4% | -1.8% | -6.4% | strong-down | 🟡 Watch |
| ISRG | $475.47 | 39 ↓ | -3.0% | +0.3% | -5.7% | strong-down | 🟡 Watch |
| ILMN | $124.02 | 49 ↓ | -0.3% | +5.7% | +5.4% | weak-down | 🟡 Hold |
| BIIB | $182.13 | 45 ↓ | -2.8% | -1.0% | -5.2% | weak-down | 🟡 Hold |
| GILD | $137.72 | 37 ↓ | -5.1% | -3.3% | -8.5% | weak-down | 🟡 Hold |
| AMGN | $346.43 | 35 ↓ | -6.8% | -5.2% | -7.6% | weak-down | 🟡 Hold |
| REGN | $733.70 | 40 ↓ | -4.2% | -1.4% | -5.9% | weak-down | 🟡 Hold |
| VRTX | $455.65 | 44 ↓ | -3.9% | -3.4% | -4.5% | weak-down | 🟡 Hold |
| DXCM | $66.82 | 42 ↓ | -4.1% | +3.5% | -8.6% | strong-down | 🟡 Watch |
| BEAM | $24.92 | 40 ↓ | -7.8% | -2.0% | -9.7% | weak-down | 🟡 Watch |
| LEGN | $17.56 | 41 ↓ | -6.6% | -5.6% | -3.1% | strong-down | 🔴 Broken |
| NTLA | $13.01 | 49 | -3.6% | +0.3% | +2.9% | strong-up | 🟡 Neutral |
| SRPT | $16.74 | 43 | -2.0% | -3.2% | -11.3% | strong-down | 🔴 Broken |
| DNA | $6.74 | 42 ↓ | -6.4% | -1.0% | -26.9% | strong-down | ❌ Avoid |
| IQV | $165.02 | 38 ↓ | -2.9% | +0.6% | -0.4% | down | 🟡 Watch |
| MRNA | $51.39 | 51 | -3.1% | -2.8% | +3.1% | strong-up | 🔒 Hold |
| EDIT | $2.37 | 55 | +4.3% | -8.9% | +32.4% | weak-up | ⚠️ Extended |
| PTGX | $98.85 | 62 | +5.4% | +5.2% | +19.4% | strong-up | 🔒 Hold |
| EXAS | $104.96 | 76 ↑ | +1.3% | +0.3% | +1.5% | strong-up | ⚠️ Overbought |
| XBI | $120.60 | 41 ↓ | -3.6% | -1.4% | -3.4% | weak-down | 🟡 ETF Neutral |
| LABU | $142.26 | 39 ↓ | -12.4% | -4.7% | -12.8% | weak-down | 🟡 3x ETF |
Tier Analysis
Tier 1 — Extreme Oversold (RSI < 30) / Potential Entry
ECL (RSI 18), MDT (RSI 25), ABBV (RSI 28), BMRN (RSI 29), A (RSI 28), LLY (RSI 30): This is oversold across the board, but the difference between "bouncing" and "continuing to fall" depends entirely on macro. Life science tools (DHR, TMO, A, IQV) are in a structural de-rating — NIH/FDA headwinds are real. ABBV near RSI 28 with a 5yr +134% run is a different story — quality compounder at an actual discount.
Tier 2 — Broken or Falling Knives
NVO (-55% from 52wk high, death cross), BNTX (-29%, -20.4% 30D), CRSP (-41% from high), RARE (-46% from high), DNA (-64% from high): Thesis-broken or structurally impaired. These aren't oversold dips; they're different companies than they were 12 months ago.
Tier 3 — Holding / Relative Strength
PTGX ($98.85, RSI 62, +19.4% 30D): The only true leader. Small-cap oncology running its own race. MRNA ($51.39, RSI 51, +47.3% 3M): Massively recovered off lows — thesis partially rehabilitated but elevated. EXAS ($104.96, RSI 76): At new highs, now overbought. Don't chase.
Entry Zones
| Stock | Current | Zone | RSI | 30D% | Action | Notes |
|---|---|---|---|---|---|---|
| ABBV | $204.75 | <$200 | 28 ↓ | -8.9% | ✅ Strong Buy | Quality pharma, 5yr +134%, at real discount |
| LLY | $903.48 | <$900 | 30 ↓ | -10.5% | 📈 Accumulate | GLP-1 thesis intact, first real pullback in 3 years |
| MDT | $86.32 | <$90 | 25 ↓ | -10.9% | 🔍 Research | Med-device oversold, needs catalyst |
| BMRN | $54.25 | <$55 | 29 ↓ | -15.3% | 🔍 Research | Rare disease, deep value case emerging |
| GILD | $137.72 | <$140 | 37 ↓ | -8.5% | 📈 Accumulate | HIV/oncology compounder, golden cross intact |
| VRTX | $455.65 | <$460 | 44 ↓ | -4.5% | 🔍 Watch | CF monopoly, pullback moderate |
| IONS | $70.83 | <$75 | 31 ↓ | -14.8% | 🔍 Research | RNA therapeutics, RSI approaching oversold |
Action Matrix
| Action | Stocks | Why |
|---|---|---|
| ✅ STRONG BUY | ABBV | RSI 28, 5yr compounder at real discount |
| 📈 ACCUMULATE | LLY, GILD | LLY first real dip; GILD HIV/oncology thesis |
| 🔒 HOLD | PTGX, MRNA, EXAS | Leaders, don't trim yet |
| 🔍 WATCH | MDT, BMRN, IONS, VRTX | Oversold, needs catalyst confirmation |
| ⚠️ AVOID | EXAS | RSI 76, overbought — don't chase new highs |
| ❌ DON'T BUY | NVO, BNTX, CRSP, RARE, DNA, RXRX | Broken thesis, falling knives |
| 🚨 EXIT | SRPT, LEGN | No floor visible, avoid dip-buying |
What Changed vs 2026-03-12
- ABBV new to extreme oversold: Was RSI 49, now RSI 28 — dropped nearly 10% in a week. Major shift.
- LLY approaching capitulation: RSI 41→30, crossed the oversold threshold. First meaningful entry signal in years.
- EXAS ripped to RSI 76: New 52wk high, overbought. Was RSI 54 last scan.
- MRNA cooling: Was RSI 60, +35.9% 30D. Now RSI 51, +3.1% 30D — extended rally fading.
- PTGX still running: Maintains momentum, now +19.4% 30D vs prior +16.2%.
- Life science tools (DHR, TMO, A) remain in structural selloff with no floor in sight.
Key Discoveries
| Discovery | Implication |
|---|---|
| ABBV at RSI 28 | Best quality-at-discount setup in biotech right now |
| LLY first real capitulation signal | GLP-1 thesis intact; RSI 30 entry signal historically reliable for LLY |
| EXAS overbought at RSI 76 | Take profits if holding; don't initiate |
Open Questions
- Are life science tools (DHR, TMO, A, IQV) facing structural de-rating from NIH/FDA budget cuts, or is this a temporary oversold bounce opportunity?
- NVO: Is there a floor at $36 or does this continue to $25-30 range as weight loss competition intensifies?
- PTGX: Can the oncology momentum sustain without broader biotech participation?
Related
10 eventsNo direct external sources are attached to this read.